Investors Urged to Act on Regeneron Class Action Lawsuit Before March 10, 2025

Levi & Korsinsky, LLP has issued a notice to investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regarding a class action lawsuit over alleged securities fraud. Investors who suffered losses during the period from November 2, 2023, to October 30, 2024, have been encouraged to reach out to the firm before March 10, 2025. This lawsuit claims that the company misled shareholders by providing false or misleading statements related to its primary product, Eylea.

Class Definition

The class action aims to represent investors affected by alleged fraudulent practices tied to the sales of Eylea, which treated serious eye conditions. The complaint outlines several problematic actions by the company. Notably, it claims Regeneron paid credit card fees to distributors under conditions that led to inflated prices for patients purchasing the medication with credit cards, effectively misrepresenting sales data and revenue figures to shareholders and regulatory agencies.

Allegations and Misconduct

According to the filed complaint:
1. Regeneron allegedly compensated distributors to prevent them from charging patients higher prices when using credit cards to purchase Eylea.
2. This created an artificial reduction in the reported sales price of Eylea, misleading shareholders about its true market performance.
3. The payments made under this scheme were not disclosed as price concessions, resulting in an overstatement of the Average Selling Price (ASP) reported to federal authorities, which potentially violated the False Claims Act.
4. The lawsuit further claims that misleading statements made by the company regarding its operations and sales led many investors to believe in a more favorable outlook than was accurate.

Legal Timeline and Next Steps

Investors affected by these claims must act quickly, as the deadline for requesting to be appointed as lead plaintiff is March 10, 2025. It is crucial to note that potential class members can still recover losses even if they do not choose to take on the role of lead plaintiff.

Participants in this class action are not required to pay any out-of-pocket costs and can engage in the legal process without financial obligation, as Levi & Korsinsky operates on a contingency basis.

Why Choose Levi & Korsinsky?

Levi & Korsinsky boasts over two decades of experience in securities litigation, having successfully secured hundreds of millions of dollars for shareholders over the years. Their reputation as one of the top firms in this field is solidified by their inclusion in ISS Securities Class Action Services' Top 50 Report for seven consecutive years.

Contact Information

Investors who believe they are affected should contact Levi & Korsinsky as soon as possible. Interested parties can get in touch with Joseph E. Levi, Esq. at (212) 363-7500 or via email at [email protected].

For more in-depth information, visit their official website at www.zlk.com, or directly access the lawsuit submission form.

As the regulatory landscape continues to evolve, it is essential for shareholders to stay informed and proactive about their investments and associated risks. This class action could have significant implications for Regeneron and its stakeholders as the lawsuit unfolds.